Novel biomarkers of immunotherapy outcomes and immune-related adverse events

4 August 2022


  • Dr. Caroline Robert, PhD, MD – Head of Dermatology. Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM
  • Dr. Jessica Hassel, MD – Section Head of Dermato-Oncology, National Centre for Tumor Diseases (NCT) Heidelberg, Germany
  • Dr. Scott Chandler, Global Head of Personalized Health Care (PHC) Safety, MD – F. Hoffmann-La Roche
  • Moderator:-Dr. Anna Lisa Jenkins, FRCP


There is significant interest in the role that the B cell response plays in cancer patients’ anti-tumour response. The autoantibody biomarker class is increasingly being recognized as a powerful tool and critical biological mediator of the cancer-immunity interplay. Autoantibodies targeting tumour and self-antigens may serve as biomarkers of anti-tumour response and auto-immunity. As these biomarkers can be measured in patient sera, they hold great potential as routine clinical biomarkers in immuno-oncology.

This webinar explores the role of autoantibodies in predicting survival and immune related adverse events (irAE) in patients receiving cancer immunotherapy.

Autoantibodies in immuno-oncology